Cite
HARVARD Citation
Balzarotti, M. et al. (n.d.). B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL). Leukemia & lymphoma. 57 (10), pp. 2375-2381. [Online].